UnknownPhase 2NCT02866370
Study Of Nintedanib Compared To Chemotherapy in Patients With Recurrent Clear Cell Carcinoma Of The Ovary Or Endometrium
Studying Clear cell adenocarcinoma of the ovary
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- NHS Greater Glasgow and Clyde
- Principal Investigator
- Rosalind GlasspoolNHS Greater Glasgow and Clyde
- Intervention
- Nintedanib(drug)
- Enrollment
- 120 enrolled
- Eligibility
- 18 years · FEMALE
- Timeline
- 2015 – 2021
Study locations (17)
- Beatson West of Scotland Cancer Centre, Glasgow, Lanarkshire, United Kingdom
- Ninewells Hospital, Dundee, Tayside, United Kingdom
- Clatterbridge Cancer Centre, Liverpool, Wirral, United Kingdom
- Belfast City Hospital (Northern Ireland Cancer Centre), Belfast, United Kingdom
- Bristol Heamatology and Cancer Centre, Bristol, United Kingdom
- Velindre Hospital, Cardiff, United Kingdom
- Kent & Canterbury Hospital, Kent, United Kingdom
- Queen Elizabeth Queen Mother Hospital, Kent, United Kingdom
- William Harvey Hospital, Kent, United Kingdom
- St James Hospital, Leeds, United Kingdom
- Guy's Hosital, London, United Kingdom
- Royal Marsden Hospital, London, United Kingdom
- St Bartholomew's Hospital, London, United Kingdom
- University College London Hospital, London, United Kingdom
- The Christie Hospital, Manchester, United Kingdom
- +2 more locations on ClinicalTrials.gov
Collaborators
Boehringer Ingelheim · Cancer Research UK · European Organisation for Research and Treatment of Cancer - EORTC · Nordic Society of Gynaecological Oncology - Clinical Trials Unit · ARCAGY/ GINECO GROUP
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02866370 on ClinicalTrials.govOther trials for Clear cell adenocarcinoma of the ovary
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT06677190Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic OriginDana-Farber Cancer Institute
- RECRUITINGPHASE1, PHASE2NCT06065462Safety and Efficacy of Targeting PP2A in Ovarian Clear Cell Carcinoma Using Dostarlimab and LB-100M.D. Anderson Cancer Center
- RECRUITINGNCT06279104A Comparative Study of the Treatment of Real-world Patients With Clear Cell Carcinoma of the OvaryTongji Hospital
- ACTIVE NOT RECRUITINGPHASE2NCT05296512Pembrolizumab and Lenvatinib in Clear Cell Ovarian CancerElizabeth K. Lee MD
- ACTIVE NOT RECRUITINGPHASE2NCT05032040A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary MalignanciesXencor, Inc.
- ACTIVE NOT RECRUITINGPHASE1NCT05226507A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian CancerNuvectis Pharma, Inc.
- RECRUITINGPHASE1, PHASE2NCT04104776A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and LymphomasNovartis Pharmaceuticals
- ACTIVE NOT RECRUITINGPHASE2NCT03348631Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial CancerNational Cancer Institute (NCI)